Archives
-
BIBR 1532: Telomerase Inhibition Workflows
2026-09-08
BIBR 1532 provides a practical route to dissect hTERT-dependent telomerase activity, cancer cell proliferation inhibition, and apoptosis induction in leukemia cells. This guide connects short-term molecular assays with longitudinal telomere studies while distinguishing telomerase blockade from DNA-damage-driven telomere attrition.
-
PTH (1-34) peptide fragment in kidney models
2026-09-08
Use the PTH (1-34) peptide fragment to connect receptor pharmacology with bone remodeling, calcium biology, and spatially organized kidney assembloid assays. This workflow emphasizes controlled exposure, compartment-specific readouts, and troubleshooting for reproducible PTH/PTHrP receptor signaling studies.
-
BKT140 (BL-8040) CXCR4 Antagonist Guide
2026-09-07
BKT140, also called BL-8040 and TF 14016, is an orally bioavailable CXCR4 antagonist used in cancer biology and hematopoietic stem-cell mobilization research. It connects CXCR4-mediated chemotaxis inhibition with tumor-cell migration, apoptosis, xenograft growth, and translational cell-mobilization assays.
-
Regorafenib, RRM2, and Melanoma Progression
2026-09-07
A 2024 iScience study shows that Regorafenib suppresses melanoma growth, invasion, and metastasis by reducing RRM2 and modulating ERK/E2F3 signaling. Its combination of RNA sequencing, functional assays, rescue experiments, and in vivo validation provides a mechanistic framework for studying multikinase inhibitor activity beyond angiogenesis.
-
SNORA38B and Immune Checkpoint Blockade in NSCLC
2026-09-05
Zhuo and colleagues identify SNORA38B as an oncogenic small nucleolar RNA that links tumor-cell signaling with an immunosuppressive microenvironment in non-small cell lung cancer. Their data support a SNORA38B–E2F1–GAB2/AKT/mTOR axis and show that SNORA38B inhibition can improve the response to immune checkpoint blockade in preclinical models.
-
Diminazene Aceturate and ACE2 in Septic Cardiomyopathy
2026-09-04
A February 2024 study examined how ACE2 activation affects sepsis-induced cardiomyopathy in C57BL/6 mice, using diminazene aceturate and MLN-4760 as pharmacological probes. The findings connect ACE2 activity with MasR-Sirt1-mediated mitochondrial biogenesis and provide a mechanistic framework for ACE2 activation research, while also highlighting the limits of interpreting a trypanocidal compound outside parasite models.
-
Faropenem Transport via Renal Npt1
2026-09-04
The 2000 reference study identified mouse Npt1 as a luminal renal transporter capable of moving the penem antibiotic faropenem. Its Xenopus oocyte experiments showed sodium-independent, chloride-sensitive uptake and markedly enhanced efflux, providing a mechanistic basis for active renal secretion and a framework for interpreting faropenem disposition.
-
Drug Responses in Cancer: Better In Vitro Metrics
2026-09-03
Hannah Schwartz’s dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer response. Its central contribution is a framework for separating growth inhibition from cell killing, improving endpoint selection, time-course interpretation, and comparison of drug effects in vitro.
-
FBXO22 Degraders and 2-PCA Recruitment Ligand
2026-09-03
This bioRxiv preprint introduces chemical probes that both interrogate FBXO22 function and expand its use as an E3 ligase recruiter for targeted protein degradation. The study identifies a potent FBXO22 degrader, defines a minimal diamine-based self-degradation motif, and uses 2-pyridinecarboxaldehyde to recruit FBXO22 for degradation of BRD4 and CDK12.
-
Polybrene (Hexadimethrine Bromide) Guide
2026-09-02
A scenario-based guide to using Polybrene (Hexadimethrine Bromide) 10 mg/mL, SKU K2701, for more interpretable viral transduction, DNA transfection, and downstream cell viability or proliferation assays. It covers mechanism, compatibility controls, storage, optimization, data interpretation, and practical vendor-selection criteria.
-
Methyl-β-cyclodextrin: Membrane Workflow Guide
2026-09-02
Methyl-β-cyclodextrin (MβCD, SKU C6939) supports controlled membrane cholesterol extraction for experiments focused on membrane organization, fluidity, and cholesterol-sensitive signaling. It is a research reagent only; concentration, exposure time, solvent, and cell-model compatibility should be established experimentally rather than inferred as universal conditions.
-
Selective Autophagy and IRF3 Stability in Antiviral Immunity
2026-09-01
The reference study identifies CALCOCO2/NDP52-mediated selective autophagy as a virus load-dependent mechanism that removes IRF3 and limits excessive type I interferon signaling. It further shows that PSMD14/POH1 preserves IRF3 by removing K27-linked ubiquitin chains at lysine 313, revealing how ubiquitination and autophagic turnover cooperate to balance antiviral activation with immune suppression.
-
Regorafenib: From Kinase Breadth to RRM2 Biology
2026-09-01
Regorafenib (BAY 73-4506) is more than a broad multikinase inhibitor. Preclinical evidence connects its antiangiogenic and oncogenic signaling effects with RRM2 suppression and ERK/E2F3 disruption in melanoma. This article translates those findings into practical assay design, biomarker strategy, and translational decision-making.
-
Merimepodib (VX-497) for IMPDH Research
2026-08-31
Merimepodib (VX-497) connects guanine-nucleotide depletion with practical antiviral, lymphocyte, and proliferation assays. This workflow-centered guide shows how to use its selective IMPDH mechanism, guanosine rescue, and cell-model comparisons to distinguish pathway-specific effects from nonspecific toxicity.
-
5-Methyl-CTP for Robust mRNA Synthesis
2026-08-31
Learn how 5-Methyl-CTP can be integrated into in vitro transcription workflows to evaluate enhanced mRNA stability and improved mRNA translation efficiency. A practical, control-driven workflow connects nucleotide selection with vaccine-oriented mRNA drug development while separating product capabilities from evidence generated in animal studies.